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general terms, the appeal of the
based around an argument that 
some patients for whom other m
work and that it could be used s• The Therapeutic Goods Administration determined in 
November 2011 that dextropropoxyphene should be 
removed from the Australian Register of Therapeutic 
Goods. This is consistent with this drug’s removal from 
the market in many other developed countries.
• However, dextropropoxyphene is still on the market in 
Australia owing to a series of appeals made to the 
Administrative Appeals Tribunal (AAT) by the drug’s 
manufacturer.
• There is a difference between the standards by which the 
AAT judges the safety and efficacy of medicines and the 
standards used for registering therapeutic goods by 
regulatory agencies worldwide.
• This raises the question as to whether the appeal process 
against TGA decisions appropriately serves the 
Australian public interest.
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I November 2011, the delegate of the Secretary of thepartment of Health and Ageing gave notice that theerapeutic Goods Administration (TGA) intended to
ve dextropropoxyphene (brand names Di-Gesic and
Doloxene) from the Australian Register of Therapeutic
Goods.1
This followed a review of the safety and efficacy of
medicines containing dextropropoxyphene. The TGA
“determined that the overall risk of serious adverse reac-
tions outweighs any benefits that may be provided by
these medicines”.2 The main concern was the risk of
sudden death from cardiotoxicity (not shared by other
opioid drugs), in the setting of renal impairment, drug
interactions and accidental or deliberate overdose.2-6
Evidence against dextropropoxyphene has been accu-
mulating for over 30 years.3 The drug has been removed
from the market by medicine regulators in the United
Kingdom (2004), European Union (2009), United States
(2010), New Zealand (2010) and elsewhere.2 Over a dec-
ade ago, the Australian Pharmaceutical Benefits Advisory
Committee (PBAC) recommended removal of subsidies for
dextropropoxyphene, and the Australian Medicines Hand-
book and Therapeutic Guidelines advised against using
the drug.5,6 However, dextropropoxyphene remains on the
market in Australia in 2013, 18 months after the TGA’s
decision to delist it, owing to a series of legal appeals by
the drug’s manufacturer before the Administrative Appeals
Tribunal (AAT).1
Deregistration of dextropropoxyphene 
in the AAT
The manufacturer of dextropropoxyphene in Australia,
Aspen Pharmacare Australia Pty Ltd (Aspen), asked the
Minister for Health and Ageing to reconsider the deregis-
tration decision, but in January 2012 it was reaffirmed.
The manufacturer then appealed that decision to the
AAT. Both the manufacturer and the TGA accepted that
the ultimate issue in the appeal was whether the “quality,
safety or efficacy” of each drug “is unacceptable” within
the meaning of section 30(2)(a) of the Therapeutic Goods
Act 1989 (Cwlth) (the TG Act).
The AAT appeal was heard by Justice Kerr, President of
the Tribunal, and Senior Member Dr Teresa Nicoletti.
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 manufacturer, Aspen, was
the drug was efficacious in
oderate analgesics did not
afely provided patients did
not take excessive doses, and if the prescribing indications,
contraindications and warnings were all carefully
observed.1 The manufacturer also indicated [para 100]1
that it would be prepared to enter into contractual obliga-
tions with all pharmacies retailing dextropropoxyphene to
supply it only on production of a signed statement from
the prescribing doctor and countersigned by the patient
about awareness of the risks. To obtain this stay, Aspen
undertook to add significant safety warnings to the prod-
uct information and consumer medicine information for
Di-Gesic and Doloxene highlighting, among other things,
that products containing dextropropoxyphene had
recently been associated with substantial prolongation of
the QT interval. Aspen also agreed to write “dear doctor”
and “dear pharmacist” letters, in a form approved by the
TGA, drawing attention to the additional safety warnings
[para 11].1
Evidence was tendered to the AAT that despite regula-
tory decisions to remove dextropropoxyphene from gen-
eral availability in the UK and US, it continued to be
available under prescription in those jurisdictions [para
94].1 Rejecting arguments from the TGA’s counsel that the
drug be made available only under the Special Access
Scheme and to authorised prescribers (s19 TG Act) (it had
only remained available after the UK ban on this sort of
scheme), the AAT decided to remit the matter again to the
Minister to see if agreement could be reached under s28 of
the TG Act for the drug to remain available with “highly
visible warnings and in blister packs designed to minimise
the risk of misuse” [paras 99 and 103].1 The AAT also
indicated that if the manufacturer still felt aggrieved by the
TGA decision it could return to the AAT to continue its
appeal. The manufacturer ultimately took up this option,
and in April 2013 the AAT upheld the appeal in its final
decision on this matter.7257MJA 199 (4) · 19 August 2013
For debateRole of the AAT in Australian therapeutic 
drug regulation
The AAT is usually the final hurdle for the TGA in regard to
appeals against drug regulatory decisions in Australia. The
role of the AAT is “to provide independent merits review of
administrative decisions”.8
The Tribunal reviews a wide range of administrative 
decisions made by Australian Government ministers, 
departments and agencies . . . The Tribunal aims to 
provide a review mechanism that is fair, just, 
economical, informal and quick.8
Most of the AAT’s work relates to review of decisions
made in regard to social security, worker’s compensation
and taxation; only 12 of 5682 applications lodged before
the AAT in the past financial year related to therapeutic
goods, and appeals lodged by pharmaceutical companies
often took over a year to resolve.9 Fighting litigation is
expensive and time-consuming for the TGA; it takes
resources away from its core roles, and the threat of legal
appeal may undermine the capacity for regulators to make
decisions solely in the best interests of public health.10,11
How well is the AAT equipped to make final judgments
concerning the safety and efficacy of medicines? How well
does the TG Act support the primary aim of promptly
making scientifically sound decisions in the best interests
of public health? Under the TG Act, the initial decision for
deregistration of a medicine is made by the government on
the grounds that safety, quality and efficacy are unaccept-
able. This can be contested by the manufacturer, who has
the right to request the Minister to reconsider the decision;
and then, if the manufacturer finds that outcome unsatis-
factory, they can apply to the AAT for independent merits
review of the decision.
In conducting that review, the AAT is not required to
judge safety and efficacy by the usual standards set down
for registering therapeutic goods by regulatory agencies
worldwide — that is, on evidence of efficacy from clinical
trials.12 The interim AAT judgment in this case stated:
There is no case law known to the Tribunal that 
suggests that the words ‘safety or efficacy’ should be 
construed otherwise than as ordinary English words, 
albeit read in the context of the Act as a whole
and refers to the Macquarie and Oxford dictionaries.1
Efficacy becomes “ability to bring about the intended
result”. Evidence on efficacy presented to the AAT
included patients’ and doctors’ opinions, 1998 Australian
Drug Evaluation Committee minutes, and a 1984 publica-
tion from an industry-sponsored symposium involving
reanalysis of small numbers of patients from previously
published studies.1
Notably, the clinical trial data that would be a require-
ment for new drugs for which manufacturers are seeking
TGA registration were not present in this case. Dextropro-
poxyphene gained registration through the process of
“grandfathering” after the commencement of the TG Act,
and the AAT did not compel the production of such data.
In contrast, regulators today require that evidence of effi-
cacy comes from clinical trials conducted to established
regulatory standards.12
The TGA submitted in the 2012 AAT hearing that after
the banning of dextropropoxyphene in the UK “there was
a significant reduction in the rate of deaths by suicide and
no commensurate increase in the number of deaths associ-
ated with other analgesics”1,4 (Box). However, the AAT
judgment referred to “the straightforward and inescapable
mathematical consequences” of these data being that
there had been an increase in suicidal poisoning by other
drugs.1 The AAT made the following comments about the
expert witnesses who agreed with the TGA’s interpretation
of these data:
. . . it was plain that both witnesses were highly resistant 
to conceding any point that might possibly be thought 
to assist the interests of the Applicant. This was 
particularly noticeable in both cases in respect of the 
Hawton et al evidence.1 [para 25]
The figure in the Box shows the data4 referred to in the
judgment (the ban was phased in over the 3 years 2005–
2007). The reduction in all drug suicides (362 fewer in 2008
than 2004) was greater than that from fatal poisonings
attributed solely to dextropropoxyphene (196 fewer), sug-
gesting that there may also have been a large additional
reduction in mixed-drug overdoses. The frequency of
other analgesic poisonings did not change significantly
over 13 years (the rate varied between 209 and 287, but the
linear trend was horizontal [ 0.5 deaths/year] and the
2010 data are equal to the long-term median [257]).
Scientific thinking understands that minor year-to-year
fluctuations are expected and are simply statistical noise
rather than signals.
In another example, the manufacturer7 and the AAT
[para 44]1 have also made much of the fact that there were
more deaths recorded in the past decade in New South
Wales coronial inquiries from codeine, paracetamol and
tramadol than from dextropropoxyphene; however, no
attempt was made to put that into perspective by adjusting
for the vastly different rates of use.
The TGA has a statutory obligation under the TG Act to
protect Australians against risks posed by unsafe, poor-
quality and low-efficacy pharmaceuticals. In legal terms,
Deaths from Co-proxamol* and other analgesic poisoning, 
and suicide by drug poisoning, United Kingdom, 1998–2010†
* UK brand name for dextropropoxyphene–paracetamol. † Graph drawn 
from data from Table 2 in: Hawton K, et al. PLOS Med 2012; 9: e1001213.4 
Shading represents the period over which a ban on dextropropoxyphene 
was phased in. ◆
0
500
1000
1500
2000 2005 2010
Year
All drug suicides
N
o
. o
f 
a
n
n
u
a
l d
ea
th
s 
in
 U
K
Co-proxamol poisonings
Other analgesic poisoningsMJA 199 (4) · 19 August 2013258
For debatethe TGA administers the TG Act to ensure the quality,
safety and efficacy of any therapeutic good supplied or
produced in Australia. The TGA is responsible for licens-
ing manufacturers, approving therapeutic products, and
regulating such products once they enter the Australian
market.
The developments in Australian law, arising from both
policy and adjudicative determinations, potentially erode
the ability of the TGA to firmly uphold its mandate. For
example, the Australian Government’s decision to pay
compensation rather than fight the civil litigation concern-
ing the TGA’s action against Pan Pharmaceuticals has
much broader implications for public health, to the extent
that the decision could be interpreted as undermining the
regulatory authority of the TGA.10
The final AAT decision overruled cancellation of Di-
Gesic and Doloxene from the Register of Therapeutic
Goods by the TGA but, despite this, summarised the AAT
view on the key issues of efficacy and safety in the
following statements:
Given that neither Di-Gesic nor Doloxene have been 
found to have exceptional efficacy and that the Tribunal 
has found that the risk of accidental overdose is real — 
such that it was common ground between the parties 
that the amount of DPP contained in a single blister 
pack of either Doloxene or Di-Gesic, if combined with 
alcohol, could in a vulnerable patient be sufficient to 
create a risk of sudden death — the Tribunal has 
concluded that the safety and efficacy of Di Gesic and 
Doloxene would be acceptable if, and only if, additional 
conditions were imposed which provide a high level of 
assurance that doctors will prescribe the products (a) 
only if therapeutically justified; (b) only after they have 
considered any contraindications and any recent 
changes to the patient’s clinical presentation or medical 
status; and (c) only after they have discussed with their 
patient the appropriate use of the products and the risks 
of overdose.7 (para 44)
and
. . . the safety and efficacy of Di-Gesic and Doloxene 
would be acceptable if, and only if, there were 
conditions put in place directed at minimising the risk 
that doctors might prescribe the product if a patient’s 
history indicates that he or she is at risk of intentional 
self-harm”.7 (para 45)
The AAT expectation that doctors and patients can
comprehensively deal with the consequences of this deci-
sion contrasts with clear contemporary evidence that con-
sistent delivery of care according to guidelines does not
usually occur in the Australian health system.13
This case highlights the need to reconsider whether this
appeal process appropriately serves the Australian public
interest. Many developing countries around the world
regard Australian registration of a therapeutic good as
evidence that the drug has passed thorough scientific
review.14 The current market for dextropropoxyphene is
now almost entirely in such countries. When registration
can be contrary to TGA advice and based around civil court
proceedings rather than scientific interpretation of evi-
dence, the international reputation of Australia’s drug
regulatory system could be at stake.
Conclusion
Regulators need to consider legislation and precedents
when undertaking regulatory actions on registered drugs,
but ultimately this is a finely nuanced expert scientific
judgement about evidence of risk and benefit.15 Evidence
of harmful effects is often of lower quality and might take
many years to accumulate. An alternative appeal process
such as that used by the US Food and Drug Administra-
tion, based around independent expert panels and
ombudsmen, might be better for reviewing disputed scien-
tific evidence.16 The evidence put forward at appeals
should be restricted to that generally accepted by regula-
tory bodies. The Commonwealth Parliament could also
legislate to protect the TGA (and other scientific regula-
tors) from legal challenges against good-faith actions
designed to protect public safety; that is, when they are
acting in the presence of substantial (but not conclusive)
proof of significant harm. Such legislation might have
safeguarded the TGA from actions in the Pan litigation; the
TGA acted promptly to protect public health after discov-
ery of widespread and serious breaches in manufacturing
practice, only for taxpayers to lose over $122 million dollars
in subsequent court cases.10
There was a very long lead time during which there were
increasingly strong warnings to prescribers that the risk–
benefit ratio of dextropropoxyphene was unfavourable2,5,6
before the TGA finally sought delisting (the last of the
world’s leading drug regulatory agencies to do so).2 We are
concerned that the Australian legislative and appeal
framework and recent adverse litigation against the TGA
contributed to this delay. While acting too early restricts
drugs that are potentially still useful in some individuals,
late action has often been measured in lives lost (thou-
sands have died worldwide from dextropropoxyphene poi-
soning,3,4 and several deaths have occurred in Australia
even as this appeal has unfolded [National Coronial Infor-
mation System; unpublished data]). The TGA should be
empowered to generate further evidence, or take prompt
action on the balance of probabilities.17 There is only one
benefit to the Australian public that could come from this
current appeal — it should clearly highlight to our govern-
ment the urgent need to revise the legal appeal processes
that in our view inappropriately burden the TGA when it
decides to take action to protect the Australian people.
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